{"transactions":[{"id":711326,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:59:49.000Z","date":"2026-07-08","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":13.26,"value":13260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":60335,"source":{"system":"sec-edgar","filing":"0001757072-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707226000007/primarydocument.xml","form_type":"4"}},{"id":712914,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31472,"kind":"person","name":"KIRSCH ARTHUR S","position":1,"cik":"0001290976","reported_name":"KIRSCH ARTHUR S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T00:00:20.000Z","date":"2026-07-07","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":13.3,"value":133000.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001290976-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000129097626000004/primarydocument.xml","form_type":"4"}},{"id":727974,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-25T00:00:54.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":16161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":39321,"derivative":{"exercise_price":2.99,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":16161},"source":{"system":"sec-edgar","filing":"0002091053-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000005/primarydocument.xml","form_type":"4"}},{"id":727973,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-25T00:00:54.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":3839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":53795,"derivative":{"exercise_price":3.84,"expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":3839},"source":{"system":"sec-edgar","filing":"0002091053-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000005/primarydocument.xml","form_type":"4"}},{"id":727972,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:54.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":22.63,"value":452600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":67794,"source":{"system":"sec-edgar","filing":"0002091053-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000005/primarydocument.xml","form_type":"4"}},{"id":727971,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:54.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":16161,"price":2.99,"value":48321.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026."}],"balance_after":87794,"source":{"system":"sec-edgar","filing":"0002091053-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000005/primarydocument.xml","form_type":"4"}},{"id":727970,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:54.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":3839,"price":3.84,"value":14741.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2026."}],"balance_after":71633,"source":{"system":"sec-edgar","filing":"0002091053-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000005/primarydocument.xml","form_type":"4"}},{"id":727978,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-25T00:00:25.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":1488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":27842,"derivative":{"exercise_price":3.84,"expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":1488},"source":{"system":"sec-edgar","filing":"0002092017-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000007/primarydocument.xml","form_type":"4"}},{"id":727977,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:25.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1488,"price":22.5,"value":33480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":46403,"source":{"system":"sec-edgar","filing":"0002092017-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000007/primarydocument.xml","form_type":"4"}},{"id":727976,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:25.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":1488,"price":3.84,"value":5713.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":47891,"source":{"system":"sec-edgar","filing":"0002092017-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000007/primarydocument.xml","form_type":"4"}},{"id":727931,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-24T23:59:47.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":7438,"price":22.71,"value":168916.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":630458,"source":{"system":"sec-edgar","filing":"0001620548-26-000007","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054826000007/primarydocument.xml","form_type":"4"}},{"id":752345,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41843,"kind":"person","name":"MCGRAW BENJAMIN F III","position":1,"cik":"0001216994","reported_name":"MCGRAW BENJAMIN F III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-04T00:04:23.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":15673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15673,"derivative":{"exercise_price":19.82,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":15673},"source":{"system":"sec-edgar","filing":"0001216994-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000121699426000003/primarydocument.xml","form_type":"4"}},{"id":752343,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31472,"kind":"person","name":"KIRSCH ARTHUR S","position":1,"cik":"0001290976","reported_name":"KIRSCH ARTHUR S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-04T00:03:38.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":15673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15673,"derivative":{"exercise_price":19.82,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":15673},"source":{"system":"sec-edgar","filing":"0001290976-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000129097626000002/primarydocument.xml","form_type":"4"}},{"id":752342,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"grant","planned":true,"acquired":true,"shares":15673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15673,"derivative":{"exercise_price":19.82,"expiration_date":"2036-06-01","underlying":"Common Stock","underlying_shares":15673},"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":752341,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":600,"price":21.38,"value":12828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.06 to $21.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":17609,"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":752340,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T00:03:06.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":5456,"price":20.21,"value":110265.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.00 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":18209,"source":{"system":"sec-edgar","filing":"0001347383-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738326000003/primarydocument.xml","form_type":"4"}},{"id":752431,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-04T00:02:34.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":13512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":29330,"derivative":{"exercise_price":3.84,"expiration_date":"2033-05-11","underlying":"Common Stock","underlying_shares":13512},"source":{"system":"sec-edgar","filing":"0002092017-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000005/primarydocument.xml","form_type":"4"}},{"id":752430,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-04T00:02:34.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":16687,"price":22.74,"value":379462.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":46403,"source":{"system":"sec-edgar","filing":"0002092017-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000005/primarydocument.xml","form_type":"4"}},{"id":752429,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-04T00:02:34.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":13512,"price":3.84,"value":51886.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":63090,"source":{"system":"sec-edgar","filing":"0002092017-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000005/primarydocument.xml","form_type":"4"}},{"id":752339,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:02:08.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":16787,"price":22.74,"value":381736.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":637896,"source":{"system":"sec-edgar","filing":"0001620548-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054826000005/primarydocument.xml","form_type":"4"}},{"id":757403,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-02T00:00:12.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":false,"shares":14223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":47845,"derivative":{"exercise_price":1.71,"expiration_date":"2034-03-21","underlying":"Common Stock","underlying_shares":14223},"source":{"system":"sec-edgar","filing":"0001742496-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249626000005/primarydocument.xml","form_type":"4"}},{"id":757402,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-02T00:00:12.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":14223,"price":22.83,"value":324711.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":60835,"source":{"system":"sec-edgar","filing":"0001742496-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249626000005/primarydocument.xml","form_type":"4"}},{"id":757401,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-02T00:00:12.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":true,"shares":14223,"price":1.71,"value":24321.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."}],"balance_after":75058,"source":{"system":"sec-edgar","filing":"0001742496-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249626000005/primarydocument.xml","form_type":"4"}},{"id":757400,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-06-01T23:59:37.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":96731,"derivative":{"exercise_price":2.99,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001757072-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707226000005/primarydocument.xml","form_type":"4"}},{"id":757399,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-01T23:59:37.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":18175,"price":22.84,"value":415117.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":59335,"source":{"system":"sec-edgar","filing":"0001757072-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707226000005/primarydocument.xml","form_type":"4"}},{"id":757398,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-01T23:59:37.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":2.99,"value":44850.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026."}],"balance_after":77510,"source":{"system":"sec-edgar","filing":"0001757072-26-000005","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707226000005/primarydocument.xml","form_type":"4"}},{"id":806028,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:24:42.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":69315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":69315,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":69315},"source":{"system":"sec-edgar","filing":"0002092017-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201726000003/primarydocument.xml","form_type":"4"}},{"id":806027,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Dev. Operations"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:24:26.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":73892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":73892,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":73892},"source":{"system":"sec-edgar","filing":"0002091053-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105326000003/primarydocument.xml","form_type":"4"}},{"id":805962,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:23:59.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":51117,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":51117,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":51117},"source":{"system":"sec-edgar","filing":"0001678620-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862026000003/primarydocument.xml","form_type":"4"}},{"id":805961,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:23:38.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":98946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":98946,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":98946},"source":{"system":"sec-edgar","filing":"0001757072-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707226000003/primarydocument.xml","form_type":"4"}},{"id":805960,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:23:19.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":115279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":115279,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":115279},"source":{"system":"sec-edgar","filing":"0001742496-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249626000003/primarydocument.xml","form_type":"4"}},{"id":805959,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-04-17T21:23:03.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":291420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":291420,"derivative":{"exercise_price":26.77,"expiration_date":"2036-04-15","underlying":"Common Stock","underlying_shares":291420},"source":{"system":"sec-edgar","filing":"0001620548-26-000003","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054826000003/primarydocument.xml","form_type":"4"}},{"id":893833,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-19T21:30:02.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":358680,"price":27.88,"value":9999998.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities held of record by LSP 7 Cooperatief UA (\"LSP 7\"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares."}],"balance_after":5288313,"source":{"system":"sec-edgar","filing":"0001193125-26-059500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526059500/ownership.xml","form_type":"4"}},{"id":897631,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-19T02:19:40.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":358680,"price":27.88,"value":9999998.4,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":5288313,"source":{"system":"sec-edgar","filing":"0002094941-26-000002","document":"form4-02192026_020236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494126000002/form4-02192026_020236.xml","form_type":"4"}},{"id":901471,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":23279,"kind":"person","name":"RA Capital Nexus Fund III, L.P.","position":3,"cik":"0001883840","reported_name":"RA Capital Nexus Fund III, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T00:28:03.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":35868,"price":27.88,"value":999999.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by the Fund."}],"balance_after":2710293,"source":{"system":"sec-edgar","filing":"0001231919-26-000164","document":"form4-02182026_120251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000123191926000164/form4-02182026_120251.xml","form_type":"4"}},{"id":961242,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T12:07:35.000Z","date":"2025-12-19","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":17.35,"value":17350.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":4026,"source":{"system":"sec-edgar","filing":"0001012975-25-000937","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000937/form4.xml","form_type":"4"}},{"id":962253,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-19T21:06:11.000Z","date":"2025-12-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":18.44,"expiration_date":"2035-12-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001678620-25-000013","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862025000013/primarydocument.xml","form_type":"4"}},{"id":972859,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-12-11T21:23:02.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":28138,"price":17.84,"value":501981.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":654683,"source":{"system":"sec-edgar","filing":"0001620548-25-000011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054825000011/primarydocument.xml","form_type":"4"}},{"id":972909,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:22:38.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":7513,"price":17.84,"value":134031.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":49578,"source":{"system":"sec-edgar","filing":"0002092017-25-000009","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201725000009/primarydocument.xml","form_type":"4"}},{"id":972857,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:22:07.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":13624,"price":17.84,"value":243052.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":60835,"source":{"system":"sec-edgar","filing":"0001742496-25-000012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249625000012/primarydocument.xml","form_type":"4"}},{"id":972908,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock","published_at":"2025-12-11T21:21:25.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":5074,"price":17.84,"value":90520.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":67794,"source":{"system":"sec-edgar","filing":"0002091053-25-000009","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105325000009/primarydocument.xml","form_type":"4"}},{"id":972858,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:20:50.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":13290,"price":17.84,"value":237093.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":62510,"source":{"system":"sec-edgar","filing":"0001757072-25-000010","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707225000010/primarydocument.xml","form_type":"4"}},{"id":972856,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:18:49.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":1478,"price":17.84,"value":26367.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":270818,"source":{"system":"sec-edgar","filing":"0001678620-25-000011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862025000011/primarydocument.xml","form_type":"4"}},{"id":1002315,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2508575,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":294502},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002314,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002313,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002312,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2104740,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":267367},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002311,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":1895260,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240756},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002310,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7230283,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908821},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002309,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2582243,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324578},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002308,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3572816,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":419441},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002307,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7145647,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":838886},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002306,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":294502,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":294502,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002305,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1632441,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":1632441,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002304,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1441032,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":1441032,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002303,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":5889699,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":691441},"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002302,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":12924620,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1517329},"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002301,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":92904,"price":16,"value":1486464.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":784345,"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002300,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":1157096,"price":16,"value":18513536.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":2674425,"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002299,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":691441,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held directly by the Nexus Fund III."}],"balance_after":691441,"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002298,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:26:30.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1517329,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\"). The general partner of the Adviser is RA Capital Management GP, LLC (the\n\"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":1517329,"source":{"system":"sec-edgar","filing":"0001346824-25-000049","document":"form4-11122025_091126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134682425000049/form4-11122025_091126.xml","form_type":"4"}},{"id":1002297,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:25:16.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":6585011,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":773069},"source":{"system":"sec-edgar","filing":"0001876264-25-000006","document":"form4-11122025_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000187626425000006/form4-11122025_091112.xml","form_type":"4"}},{"id":1002296,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:25:16.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":5090000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":646587},"source":{"system":"sec-edgar","filing":"0001876264-25-000006","document":"form4-11122025_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000187626425000006/form4-11122025_091112.xml","form_type":"4"}},{"id":1002295,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:25:16.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":15493466,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1947477},"source":{"system":"sec-edgar","filing":"0001876264-25-000006","document":"form4-11122025_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000187626425000006/form4-11122025_091112.xml","form_type":"4"}},{"id":1002294,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:25:16.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":1562500,"price":16,"value":25000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe."}],"balance_after":4929633,"source":{"system":"sec-edgar","filing":"0001876264-25-000006","document":"form4-11122025_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000187626425000006/form4-11122025_091112.xml","form_type":"4"}},{"id":1002293,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":65693,"kind":"person","name":"LSP 7 Cooperative UA","position":1,"cik":"0001876264","reported_name":"LSP 7 Cooperative UA","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:25:16.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3367133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe."}],"balance_after":3367133,"source":{"system":"sec-edgar","filing":"0001876264-25-000006","document":"form4-11122025_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000187626425000006/form4-11122025_091112.xml","form_type":"4"}},{"id":1002421,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:24:08.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":6585011,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":773069},"source":{"system":"sec-edgar","filing":"0002094941-25-000004","document":"form4-11122025_091104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494125000004/form4-11122025_091104.xml","form_type":"4"}},{"id":1002420,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:24:08.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":5090000,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":646587},"source":{"system":"sec-edgar","filing":"0002094941-25-000004","document":"form4-11122025_091104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494125000004/form4-11122025_091104.xml","form_type":"4"}},{"id":1002419,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:24:08.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":15493466,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1947477},"source":{"system":"sec-edgar","filing":"0002094941-25-000004","document":"form4-11122025_091104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494125000004/form4-11122025_091104.xml","form_type":"4"}},{"id":1002418,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:24:08.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":1562500,"price":16,"value":25000000.0,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":4929633,"source":{"system":"sec-edgar","filing":"0002094941-25-000004","document":"form4-11122025_091104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494125000004/form4-11122025_091104.xml","form_type":"4"}},{"id":1002417,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":59138,"kind":"person","name":"Verduyn-van Weegen Felice Isabel","position":1,"cik":"0002094941","reported_name":"Verduyn-van Weegen Felice Isabel","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:24:08.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3367133,"ownership":{"direct":false,"nature":"By LSP 7 Cooperatief U.A."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held by LSP 7 Cooperatief U.A. (\"LSP 7\"). LSP 7 Management BV (\"LSP 7 Management\") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein."}],"balance_after":3367133,"source":{"system":"sec-edgar","filing":"0002094941-25-000004","document":"form4-11122025_091104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2094941/000209494125000004/form4-11122025_091104.xml","form_type":"4"}},{"id":1002292,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:22:58.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":206355,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24225},"source":{"system":"sec-edgar","filing":"0001620548-25-000009","document":"form4-11122025_091154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054825000009/form4-11122025_091154.xml","form_type":"4"}},{"id":1002291,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35735,"kind":"person","name":"Pena Luis C.","position":1,"cik":"0001620548","reported_name":"Pena Luis C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-11-12T21:22:58.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":24225,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":682821,"source":{"system":"sec-edgar","filing":"0001620548-25-000009","document":"form4-11122025_091154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000162054825000009/form4-11122025_091154.xml","form_type":"4"}},{"id":1002425,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:21:52.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3175},"source":{"system":"sec-edgar","filing":"0002092017-25-000007","document":"form4-11122025_091148.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201725000007/form4-11122025_091148.xml","form_type":"4"}},{"id":1002424,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35758,"kind":"person","name":"Patel Jeegar Pravinkumar","position":1,"cik":"0002092017","reported_name":"Patel Jeegar Pravinkumar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-12T21:21:52.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":57091,"source":{"system":"sec-edgar","filing":"0002092017-25-000007","document":"form4-11122025_091148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2092017/000209201725000007/form4-11122025_091148.xml","form_type":"4"}},{"id":1002290,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:20:45.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3175},"source":{"system":"sec-edgar","filing":"0001742496-25-000010","document":"form4-11122025_091142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249625000010/form4-11122025_091142.xml","form_type":"4"}},{"id":1002289,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":40133,"kind":"person","name":"Moss Gregory S.","position":1,"cik":"0001742496","reported_name":"Moss Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-12T21:20:45.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3175,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":3175,"source":{"system":"sec-edgar","filing":"0001742496-25-000010","document":"form4-11122025_091142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000174249625000010/form4-11122025_091142.xml","form_type":"4"}},{"id":1002288,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2508575,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":294502},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002287,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002286,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"By NFLS Delta III Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities are directly held by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002285,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2104740,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":267367},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002284,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":1895260,"ownership":{"direct":false,"nature":"By NFLS Delta III Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities are directly held by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240756},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002283,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7230283,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908821},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002282,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2582243,"ownership":{"direct":false,"nature":"By NFLS Delta III Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities are directly held by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324578},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002281,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3572816,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund I, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":419441},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002280,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7145647,"ownership":{"direct":false,"nature":"By NFLS Delta III Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities are directly held by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":838886},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002279,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":25790,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3026},"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002278,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":294502,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":294502,"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002277,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1632441,"ownership":{"direct":false,"nature":"By Pivotal bioVenture Partners Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1632441,"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002276,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1441032,"ownership":{"direct":false,"nature":"By NFLS Delta III Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Securities are directly held by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":1441032,"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002275,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":71006,"kind":"person","name":"Hopfner Robert Lorne","position":1,"cik":"0001551966","reported_name":"Hopfner Robert Lorne","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:19:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3026,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein."}],"balance_after":3026,"source":{"system":"sec-edgar","filing":"0001551966-25-000007","document":"form4-11122025_091138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000155196625000007/form4-11122025_091138.xml","form_type":"4"}},{"id":1002423,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:18:37.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1587},"source":{"system":"sec-edgar","filing":"0002091053-25-000007","document":"form4-11122025_091133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105325000007/form4-11122025_091133.xml","form_type":"4"}},{"id":1002422,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":35756,"kind":"person","name":"Drew Janice Suzann","position":1,"cik":"0002091053","reported_name":"Drew Janice Suzann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Operations"}}],"security":"Common Stock","published_at":"2025-11-12T21:18:37.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1587,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":72868,"source":{"system":"sec-edgar","filing":"0002091053-25-000007","document":"form4-11122025_091133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091053/000209105325000007/form4-11122025_091133.xml","form_type":"4"}},{"id":1002274,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:17:36.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":51588,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6056},"source":{"system":"sec-edgar","filing":"0001347383-25-000009","document":"form4-11122025_091132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738325000009/form4-11122025_091132.xml","form_type":"4"}},{"id":1002273,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":41841,"kind":"person","name":"Cohen David E","position":1,"cik":"0001347383","reported_name":"Cohen David E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:17:36.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":6056,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":23665,"source":{"system":"sec-edgar","filing":"0001347383-25-000009","document":"form4-11122025_091132.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000134738325000009/form4-11122025_091132.xml","form_type":"4"}},{"id":1002272,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:16:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3175},"source":{"system":"sec-edgar","filing":"0001757072-25-000008","document":"form4-11122025_091140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707225000008/form4-11122025_091140.xml","form_type":"4"}},{"id":1002271,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":31035,"kind":"person","name":"Carver Kyle","position":1,"cik":"0001757072","reported_name":"Carver Kyle","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-12T21:16:43.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":3175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":75800,"source":{"system":"sec-edgar","filing":"0001757072-25-000008","document":"form4-11122025_091140.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000175707225000008/form4-11122025_091140.xml","form_type":"4"}},{"id":1002269,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:15:24.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1587},"source":{"system":"sec-edgar","filing":"0001678620-25-000009","document":"form4-11122025_091121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862025000009/form4-11122025_091121.xml","form_type":"4"}},{"id":1002268,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:15:24.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":206355,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24225},"source":{"system":"sec-edgar","filing":"0001678620-25-000009","document":"form4-11122025_091121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862025000009/form4-11122025_091121.xml","form_type":"4"}},{"id":1002267,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":52085,"kind":"person","name":"Bauer Eugene","position":1,"cik":"0001678620","reported_name":"Bauer Eugene","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-12T21:15:24.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":25812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."}],"balance_after":272296,"source":{"system":"sec-edgar","filing":"0001678620-25-000009","document":"form4-11122025_091121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000167862025000009/form4-11122025_091121.xml","form_type":"4"}}],"next_cursor":"2025-11-12T21:15:24.000000Z,1002267"}